263 related articles for article (PubMed ID: 31031868)
1. Inhibition of RNA-Binding Protein Musashi-1 Suppresses Malignant Properties and Reverses Paclitaxel Resistance in Ovarian Carcinoma.
Chen H; Liu J; Wang H; Cheng Q; Zhou C; Chen X; Ye F
J Cancer; 2019; 10(6):1580-1592. PubMed ID: 31031868
[No Abstract] [Full Text] [Related]
2. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo.
Kong QW; Yang J; Li D; Ding YW; Hu YJ; Xue XC; Shi MZ; Jiang B; Zhou YY; Zhang M; Hu JD; Guo C; Chen JJ; Han YL
J Ethnopharmacol; 2023 Jan; 300():115728. PubMed ID: 36126783
[TBL] [Abstract][Full Text] [Related]
3. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
4. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
5. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
6. Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.
Miao F; Zhang X; Cao Y; Wang Y; Zhang X
BMC Cancer; 2017 Dec; 17(1):838. PubMed ID: 29228922
[TBL] [Abstract][Full Text] [Related]
7. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells.
Löblein MT; Falke I; Eich HT; Greve B; Götte M; Troschel FM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768932
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
9. [Study on the Relationship Between
Yue C; Li RH; Chen C; Liu H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 May; 49(3):337-341. PubMed ID: 30014630
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated Stem Cell Markers Musashi-1 and Musashi-2 are Associated with Therapy Resistance in Inflammatory Breast Cancer.
Haiduk TS; Sicking M; Brücksken KA; Espinoza-Sánchez NA; Eder KM; Kemper B; Eich HT; Götte M; Greve B; Troschel FM
Arch Med Res; 2023 Sep; 54(6):102855. PubMed ID: 37481823
[TBL] [Abstract][Full Text] [Related]
11. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
12. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
[TBL] [Abstract][Full Text] [Related]
13. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
14. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.
Shao L; Shen Z; Qian H; Zhou S; Chen Y
DNA Cell Biol; 2017 Dec; 36(12):1108-1116. PubMed ID: 28972400
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo.
Sureban SM; May R; George RJ; Dieckgraefe BK; McLeod HL; Ramalingam S; Bishnupuri KS; Natarajan G; Anant S; Houchen CW
Gastroenterology; 2008 May; 134(5):1448-58. PubMed ID: 18471519
[TBL] [Abstract][Full Text] [Related]
17. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
18. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
[TBL] [Abstract][Full Text] [Related]
19. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F
Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
